

THE OFFICIAL IOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

- Article Title: Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
- Authors: Christoph U. Correll, MD; Ying He, PhD; François Therrien, PharmD; Erin MacKenzie, PhD; Stine R. Meehan, PhD; Catherine Weiss, PhD; Nanco Hefting, MSc; and Mary Hobart, PhD
- **DOI Number:** 10.4088/JCP.20m13793

List of Supplementary Material for the article

- 1. <u>Table 1</u> Short-Term Studies: Baseline Demographic and Clinical Characteristics Stratified by Age (Randomized Sample)
- 2. <u>Table 2</u> Short-Term Studies: Baseline Demographic and Clinical Characteristics Stratified by Baseline Functioning (Randomized Sample)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2022 Physicians Postgraduate Press, Inc.

It is illegal to post this copyrighted PDF on any website. \bullet © 2022 Copyright Physicians Postgraduate Press, Inc.

Supplementary Material

Supplement to: Effects of brexpiprazole on functioning in patients with schizophrenia: post hoc analysis of short- and long-term studies

		•		
	Age 18–35 Years		Age 36–65 Years	
	Placebo (n=204)	Brexpiprazole 2–4 mg (n=353)	Placebo (n=327)	Brexpiprazole 2–4 mg (n=530)
Demographic characterist	ics			
Age (years), mean (SD)	28.6 (4.5)	28.1 (4.5)	46.8 (6.9)	46.4 (7.1)
BMI (kg/m ²), mean (SD)	25.8 (5.8)	25.7 (5.8)	27.0 (5.2)	27.7 (6.1)
Female, n (%)	55 (27.0)	97 (27.5)	154 (47.1)	245 (46.2)
White, n (%)	133 (65.2)	226 (64.0)	221 (67.6)	349 (65.8)
Clinical characteristics				
Age at first diagnosis (years), mean (SD)	21.1 (4.9)	21.9 (4.8)	29.9 (9.5)	29.4 (9.1)
Duration of current episode (weeks), mean (SD)	2.5 (2.4) (n=141)	2.8 (2.8) (n=299)	2.7 (2.9) (n=227)	2.4 (2.0) (n=433)
PANSS Total score, mean (SD)	97.3 (12.4) (n=201)	97.2 (12.5) (n=351)	95.6 (11.3) (n=326)	95.1 (12.3) (n=527)
CGI-S score, mean (SD)	4.9 (0.7) (n=202)	4.9 (0.6)	4.9 (0.6)	4.9 (0.6) (n=529)
PSP score, mean (SD)	44.9 (9.9) (n=199)	43.8 (10.7) (n=347)	43.8 (10.5) (n=324)	44.9 (11.0) (n=521)

Supplementary Table 1. Short-Term Studies: Baseline Demographic and Clinical Characteristics Stratified by Age (Randomized Sample)

Abbreviations: BMI=body mass index; CGI-S=Clinical Global Impressions – Severity of illness; PANSS=Positive and Negative Syndrome Scale; PSP=Personal and Social Performance scale; SD=standard deviation.

	Better Baseline Functioning		Worse Baseline Functioning				
	Placebo (n=271)	Brexpiprazole 2-4 mg (n=436)	Placebo (n=252)	Brexpiprazole 2–4 mg (n=432)			
Demographic characteristics							
Age (years), mean (SD)	39.9 (11.0)	39.6 (11.0)	40.0 (10.4)	38.6 (10.8)			
BMI (kg/m²), mean (SD)	26.8 (5.3)	27.1 (6.0)	26.3 (5.6)	26.8 (6.0)			
Female, n (%)	111 (41.0)	179 (41.1)	95 (37.7)	154 (35.6)			
White, n (%)	178 (65.7)	279 (64.0)	171 (67.9)	282 (65.3)			
Clinical characteristics							
Age at first diagnosis (years), mean (SD)	26.5 (9.4)	27.4 (9.0)	26.6 (8.8)	25.5 (8.1)			
Duration of current episode (weeks), mean (SD)	2.7 (2.7) (n=189)	2.5 (2.3) (n=369)	2.6 (2.8) (n=173)	2.6 (2.4) (n=349)			
PANSS Total score, mean (SD)	93.1 (11.0)	92.0 (11.2)	99.4 (11.6)	100.0 (12.2)			
CGI-S score, mean (SD)	4.7 (0.6)	4.7 (0.6)	5.0 (0.6)	5.1 (0.6)			
PSP score, mean (SD)	52.1 (6.9)	52.9 (7.5)	35.8 (5.6)	35.9 (6.0)			

Supplementary Table 2. Short-Term Studies: Baseline Demographic and Clinical Characteristics Stratified by Baseline Functioning^a (Randomized Sample)

^aBetter baseline functioning was defined as PSP score ≥median at baseline; worse baseline functioning was defined as PSP score <median at baseline. Patients without a baseline PSP score were excluded from this analysis.

Abbreviations: BMI=body mass index; CGI-S=Clinical Global Impressions – Severity of illness; PANSS=Positive and Negative Syndrome Scale; PSP=Personal and Social Performance scale; SD=standard deviation.